FSUE Endopharm organized a business trip for representatives of the Department of Pharmaceutical and Medical Industry Development of the Ministry of Industry and Trade of the Russian Federation to ENDOPHARM Agro and Pochep branches located in the Bryansk region.
Mikhail Fonarev, CEO of FSUE Endopharm, presented an overview of the branches’ activities to the representatives of the Department and the leadership of the Bryansk region headed by the Governor Alexander Bogomaz.
During the events, the participants of the business meeting were shown the stages of cultivation, harvesting and primary processing of opium poppy sown on 2,000 hectares in 2023.
During the conversation between Governor Alexander Bogomaz, Mikhail Fonarev, CEO of FSUE Endopharm, Dmitry Galkin, Director of the Department for Development of Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of the Russian Federation, and Dmitry Starkov, Chief Agronomist of FSUE Endopharm, some valuable recommendations were received regarding technical aspects of using fertilizers and other mineral substances at all stages of opium poppy cultivation to obtain more food poppy grains per hectare and preserve the harvest.
During the visit to the Pochep branch, the Department employees and the leaders of the Bryansk region had an opportunity to observe the production of small-scale batches of active pharmaceutical ingredients at the experimental industrial sites of the Company.
Alexander Beskopylniy, Deputy CEO and Director of Pochep Branch, and Daria Tuchapskaya, Deputy Director for Science at Pochep Branch, commented on technical aspects of production of six active pharmaceutical ingredients.
Following the familiarization with the operation of low-tonnage production facilities of the Company, a business meeting was held on the prospects of development of branches of FSUE Endopharm in the Bryansk region.
During the VC meeting, Vasily Osmakov, First Deputy Minister of Industry and Trade of the Russian Federation, confirmed the interest of the Ministry in implementing a joint investment project with FSUE Endopharm. This project is aimed at ensuring the country’s adequate supply of vital and essential drug products through the production of API and a whole range of VED list drug products, including full localization of production of opioid analgesics in the Russian Federation.
In early August 2023, Tatyana Varsobina, Deputy CEO for Economics and Finance at FSUE Endopharm, held a business meeting with representatives of PJSC Sberbank and VEB.RF at the Bryansk Region branches as part of the verification of the financial model of the investment project: “Construction, reconstruction and technical re-equipment of the industrial complex for the production of full-cycle drug products, including those made from ingredients produced in-house on the basis of FSUE Endopharm”.
The participants of the event got acquainted with already operating API production sites and those under construction, with the internal regulatory documentation confirming competence in the field of API production, as well as with technological processes and organization of construction sites. Based on the visit outcomes, the representatives of Sberbank and VEB.RF had a positive opinion on the demonstrated sites and the status of the project implementation, which will be subsequently presented at the credit committees of the banks and at the meeting of the Industrial Development Fund Commission.
FSUE Endopharm has a high level of financial stability, ensures the liquidity of all current and subsequent obligations, pursues innovative development, improves the quality and competitiveness of products. By 2026, the implementation of the investment project will make it possible to scale up production technologies for more than 65 APIs and expand the nomenclature of about 220 drug products, and launch a high-tech complex for the production of active pharmaceutical ingredients.
Comment type is not specified in the component properties.